NCT04627012View on ClinicalTrials.gov

Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

January 1, 2018

Primary Completion Date

December 30, 2021

Study Completion Date

July 1, 2023

Conditions
Hepatocellular CarcinomaAnti-PD1 AntibodyLiver Diseases
Interventions
DRUG

Lenvatinib

12 mg (or 8 mg) once daily (QD) oral dosing.

DRUG

Opdivo

3mg/mg intravenously every 3 weeks

DRUG

Camrelizumab

200mg intravenously every 3 weeks

DRUG

Keytruda

200mg intravenously every 3 weeks

DRUG

Toripalimab

240mg intravenously every 3 weeks

DRUG

Sintilimab

200mg intravenously every 3 weeks

DRUG

Tislelizumab

200mg intravenously every 3 weeks

Trial Locations (1)

510000

Second Affiliated Hospital of Guangzhou Medical University, Guangzhou

All Listed Sponsors
collaborator

Second Affiliated Hospital of Guangzhou Medical University

OTHER

lead

Sun Yat-sen University

OTHER

NCT04627012 - Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma | Biotech Hunter | Biotech Hunter